Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 6;26(23):7408.
doi: 10.3390/molecules26237408.

Exploiting the Chiral Ligands of Bis(imidazolinyl)- and Bis(oxazolinyl)thiophenes-Synthesis and Application in Cu-Catalyzed Friedel-Crafts Asymmetric Alkylation

Affiliations

Exploiting the Chiral Ligands of Bis(imidazolinyl)- and Bis(oxazolinyl)thiophenes-Synthesis and Application in Cu-Catalyzed Friedel-Crafts Asymmetric Alkylation

Mohammad Shahidul Islam et al. Molecules. .

Abstract

Five new C2-symmetric chiral ligands of 2,5-bis(imidazolinyl)thiophene (L1-L3) and 2,5-bis(oxazolinyl)thiophene (L4 and L5) were synthesized from thiophene-2,5-dicarboxylic acid (1) with enantiopure amino alcohols (4a-c) in excellent optical purity and chemical yield. The utility of these new chiral ligands for Friedel-Crafts asymmetric alkylation was explored. Subsequently, the optimized tridentate ligand L5 and Cu(OTf)2 catalyst (15 mol%) in toluene for 48 h promoted Friedel-Crafts asymmetric alkylation in moderate to good yields (up to 76%) and with good enantioselectivity (up to 81% ee). The bis(oxazolinyl)thiophene ligands were more potent than bis(imidazolinyl)thiophene analogues for the asymmetric induction of the Friedel-Crafts asymmetric alkylation.

Keywords: Friedel−Crafts alkylation; asymmetric catalysis; bis-imidazoline; bis-oxazoline; indoles; thiophene; β-nitroolefins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Previously reported potent ligand structures for asymmetric FC reaction.
Scheme 1
Scheme 1
2,5-bis(imidazolinyl)thiophene (L1L3) and 2,5-bis(oxazolinyl) thiophene (L4 and L5). Reaction conditions: (I) SOCl2 (8 mL/g), cat. DMF, 24 h, reflux; (II) i. CH2Cl2, TEA (5 eq.), −10 °C; ii. Amino alcohol (3ac) (2.1 eq.); (III) 4a, SOCl2 (8.8 mL/g), refluxed, 24 h; (IV) i. 5a, Et2O, TEA (12.0 eq.), 0 °C; ii. 2.5 eq. R1NH2 (6ac), 0 °C, then r.t., 12 h; (V) NaOH (15% aq. soln., 15 mL/g), r.t, 24 h; (VI) 4b4c, Tosylchloride (1.25 eq.), DMAP (cat. 0.1 eq.), TEA (4.0 eq.), CH2Cl2, r.t, 48 h, N2.
Figure 2
Figure 2
C2-symmetric 2,5-bis(imidazolinyl)thiophene (L1–L3) and ligands 2,5-bis(oxazolinyl)thiophene (L4 and L5) tested for the Friedel–Crafts alkylation reaction of indoles with trans-β-nitrostyrene derivatives.
Scheme 2
Scheme 2
Friedel–Crafts arylation of indole (8b) with nitrostyrene-based indole scaffold (9i and 9j).
Figure 3
Figure 3
Proposed mechanism: L5:Cu(OTf)2-catalyzed Friedel–Craft alkylation of indole with β-nitroolefin catalytic cycle.

Similar articles

Cited by

References

    1. Cai F., Pu X., Qi X., Lynch V., Radha A., Ready J.M. Chiral allene-containing phosphines in asymmetric catalysis. J. Am. Chem. Soc. 2011;133:18066–18069. doi: 10.1021/ja207748r. - DOI - PMC - PubMed
    1. Leeuwen P.W.v., Kamer P.C., Claver C., Pamies O., Dieguez M. Phosphite-containing ligands for asymmetric catalysis. Chem. Rev. 2011;111:2077–2118. doi: 10.1021/cr1002497. - DOI - PubMed
    1. Fernández-Pérez H., Etayo P., Panossian A., Vidal-Ferran A. Phosphine− phosphinite and phosphine− phosphite ligands: Preparation and applications in asymmetric catalysis. Chem. Rev. 2011;111:2119–2176. doi: 10.1021/cr100244e. - DOI - PubMed
    1. Banerjee D., Buzas A.K., Besnard C.l., Kündig E.P. Chiral n-heterocyclic carbene gold complexes: Synthesis, properties, and application in asymmetric catalysis. Organometallics. 2012;31:8348–8354. doi: 10.1021/om300917m. - DOI
    1. Yoon M., Srirambalaji R., Kim K. Homochiral metal–organic frameworks for asymmetric heterogeneous catalysis. Chem. Rev. 2012;112:1196–1231. doi: 10.1021/cr2003147. - DOI - PubMed

LinkOut - more resources